Abstract
The CXC chemokine receptor 2 (CXCR2) has attracted a considerable amount of attention as a target for therapeutic intervention due the key role this receptor plays in a number of inflammatory disorders. Over the past decade, several classes of potent, selective CXCR2 receptor antagonists have been developed as potential anti-inflammatory agents. These small-molecule chemokine receptor antagonists have demonstrated the ability to inhibit CXCR2-mediated recruitment of inflammatory cells in vitro as well as shown efficacy in vivo in various animal models of inflammation. In addition, several of the most advanced CXCR2 receptor antagonists have recently demonstrated promising proof-of-activity results in early human clinical trials. This review details the discovery and development of the 3,4-diaminocyclobut-3- ene-1,2-dione-based CXCR2 receptor antagonist class including SCH 527123 which is currently in mid-stage clinical evaluation. The medicinal chemistry efforts leading to the discovery of SCH 527123, the in vitro and in vivo pharmacology for this compound, and an overview of the clinical evaluation of SCH 527123 will also be discussed.
Keywords: CXCR2, 3, 4-diaminocyclobut-3-ene-1, 2-dione, SCH 527123
Current Topics in Medicinal Chemistry
Title: Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders
Volume: 10 Issue: 13
Author(s): Michael P. Dwyer and Purakattle Biju
Affiliation:
Keywords: CXCR2, 3, 4-diaminocyclobut-3-ene-1, 2-dione, SCH 527123
Abstract: The CXC chemokine receptor 2 (CXCR2) has attracted a considerable amount of attention as a target for therapeutic intervention due the key role this receptor plays in a number of inflammatory disorders. Over the past decade, several classes of potent, selective CXCR2 receptor antagonists have been developed as potential anti-inflammatory agents. These small-molecule chemokine receptor antagonists have demonstrated the ability to inhibit CXCR2-mediated recruitment of inflammatory cells in vitro as well as shown efficacy in vivo in various animal models of inflammation. In addition, several of the most advanced CXCR2 receptor antagonists have recently demonstrated promising proof-of-activity results in early human clinical trials. This review details the discovery and development of the 3,4-diaminocyclobut-3- ene-1,2-dione-based CXCR2 receptor antagonist class including SCH 527123 which is currently in mid-stage clinical evaluation. The medicinal chemistry efforts leading to the discovery of SCH 527123, the in vitro and in vivo pharmacology for this compound, and an overview of the clinical evaluation of SCH 527123 will also be discussed.
Export Options
About this article
Cite this article as:
P. Dwyer Michael and Biju Purakattle, Discovery of 3,4-Diaminocyclobut-3-ene-1,2-dione-Based CXCR2 Receptor Antagonists for the Treatment of Inflammatory Disorders, Current Topics in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/156802610791561246
DOI https://dx.doi.org/10.2174/156802610791561246 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Oleanolic Acid Derived from Plants: Synthesis and Pharmacological Properties of A-ring Modified Derivatives
Letters in Drug Design & Discovery Next-Generation Anticancer Metallodrugs
Current Topics in Medicinal Chemistry Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary Approach
Current Radiopharmaceuticals Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Neuroprotective Therapy for HIV Dementia
Current HIV Research Linear Poly(ethylenimine) Cross-Linked by Methyl-β-Cyclodextrin for Gene Delivery
Current Gene Therapy Studies of NVP-BEZ235 in Melanoma
Current Cancer Drug Targets Factors Affecting Quantification in PET/CT Imaging
Current Medical Imaging Recent Advances in Discovery, Biosynthesis and Genome Mining of Medicinally Relevant Polycyclic Tetramate Macrolactams
Current Topics in Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medicinal Chemistry Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Bone Marrow Stromal Cells as Targets for Gene Therapy
Current Gene Therapy Bioluminescence Imaging in Rodents: When Light Illuminates Cancer Research
Current Molecular Imaging (Discontinued) Emerging Immunotargets and Immunotherapies in Prostate Cancer
Current Drug Targets Fabrication and Evaluation of Glabridin Tip-loaded Dissolving Microneedles
Current Drug Delivery